Rapport Therapeutics, Inc. (RAPP) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company developing small molecule precision medicines for neurological and psychiatric disorders. The company focuses on its RAP technology platform, with its lead candidate, RAP-219, currently in Phase 2a trials for drug-resistant focal onset seizures and bipolar mania. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(26,732) | $(18,121) | $(50,795) | $(40,790) |
| Operating Expenses | $29,496 | $20,800 | $56,604 | $37,894 |
| Cash & Equivalents | $55,067 | $56,805 | $55,067 | $56,805 |
| Short-term Investments | $205,380 | $248,475 | $205,380 | $248,475 |
| Total Liquidity (Excl. Restricted) | $260,447 | $305,280 | $260,447 | $305,280 |
| Accumulated Deficit | $(174,540) | $(123,745) | $(174,540) | $(123,745) |
Note: The company has no revenue and no debt. Liquidity consists of cash, cash equivalents, and short-term investments.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2025, increased to $50.8 million from $40.8 million in the prior year period. This was driven by a $14.1 million increase in Research and Development (R&D) expenses and a $4.7 million increase in General and Administrative (G&A) expenses.
- R&D Spend Acceleration: R&D expenses rose primarily due to increased clinical trial costs for the RAP-219 Phase 2a trial in focal onset seizures, start-up costs for the bipolar mania trial, and increased personnel-related costs.
- Liquidity Position: Total cash and short-term investments decreased by approximately $44.8 million year-over-year, reflecting the burn rate of operations, though the company maintains a strong balance sheet with $260.4 million in liquid assets.
- Interest Income: Interest income increased to $5.8 million for the six months ended June 30, 2025, compared to $4.5 million in the prior year, due to higher cash balances from the 2024 IPO.
Guidance, Outlook, and Risks
- Clinical Outlook:
- Focal Onset Seizures: Topline results from the Phase 2a proof-of-concept trial are expected in September 2025.
- Bipolar Mania: Phase 2 proof-of-concept trial is enrolling; topline results expected in the first half of 2027.
- Diabetic Peripheral Neuropathic Pain (DPNP): The FDA placed a clinical hold on the IND for this indication in Q4 2024. The company is working to resolve the hold and expects to provide an update on trial initiation timing later in 2025.
- Liquidity Runway: Management expects existing cash and short-term investments to fund operations through the end of 2026.
- Capital Markets: In July 2025, the company established an At-The-Market (ATM) offering program to sell up to $150 million of common stock. No shares have been sold to date.
- Key Risks:
- Dependence on the success of RAP-219; failure in clinical trials would materially harm the business.
- Regulatory uncertainty regarding the clinical hold on the DPNP trial.
- Need for additional capital to fund future operations and commercialization efforts.
- Reliance on third-party manufacturers and CROs.
Investor Verification Checklist
- Verify the status and timeline for lifting the FDA clinical hold on the RAP-219 DPNP trial.
- Monitor the September 2025 announcement of topline data for the focal onset seizures Phase 2a trial.
- Track the company's cash burn rate against the stated runway to the end of 2026.
- Review the utilization of the newly established ATM program for potential dilution.
- Assess the progress of patient enrollment in the bipolar mania Phase 2 trial.